NS

Nihal Sinha

Board Director at Ensoma

London, England

Overview

Work Experience

FC

F-Prime Capital

  • Partner

    2014 - Current

    F-Prime Capital is a global venture capital firm investing in healthcare and technology companies.

TL

T-Therapeutics Ltd

  • Board Director

    2023

CT

CHARM Therapeutics

  • Board Director, Founding Investor

    2021

E

Ensoma

  • Board Director

    2023

A

AviadoBio

  • Board Director

    2020

OT

Orchard Therapeutics

  • Founding Team

    2016 - 2019

    Founding Team. Interim Medical Director.

FB

Fidelity Biosciences

  • Analyst

    2013 - 2014

    Venture capital analyst in life sciences and healthcare

TB

The Boston Consulting Group

  • Management Consultant

    2012 - 2013

OU

OXFORD UNIVERSITY HOSPITALS NHS TRUST

  • Academic Clinical Fellow

    2010 - 2012

Uo

University of Cambridge

  • Neuroscience Supervisor

    2005 - 2012

Education

Investments

T-Therapeutics

Series A

Total Funding: $60M

Elucidata

Series A

Total Funding: $23M

RIGImmune

Seed

Total Funding:

CHARM Therapeutics

Series A

Total Funding: $50M

Relevant Websites